Compare · head to head
Coherus Oncology vs Exelixis
Exelixis ranks higher overall — 360 rank 96 vs 72.
Exelixis leads on Quality (82 vs 53). Coherus Oncology leads on Growth (60 vs 49). The two are close on Safety and Sentiment.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Biotechnology |
| Size | Small | Large |
| ISIN | US19249H1032 | US30161Q1040 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | — | |
| Ranks | ||
| 360 | 72 | 96 |
| Value | NR | 65 |
| Quality | 53 | 82 |
| Growth | 60 | 49 |
| Safety | 61 | 64 |
| Sentiment | 49 | 46 |
| Quality details | ||
| Profitability | 55 | 96 |
| Cash Truth | NR | 68 |
Coherus Oncology vs IncyteCoherus Oncology vs Janux TherapeuticsCoherus Oncology vs MeiraGTxCoherus Oncology vs Bicara TherapeuticsAdd a third stock →
Full analyses: Coherus Oncology · Exelixis
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100